杜倩 1王哲 1运乃茹 2黄宇虹 2徐强 2王保和2
作者信息
- 1. 天津中医药大学,天津 300073
- 2. 天津中医药大学第二附属医院,天津 300150
- 折叠
摘要
Abstract
Objective To systematically evaluate the safety of Xianling Gubao Capsules ( XLGB ) . Methods Literatures were retrieved from PubMed, EMbase, CBM, CNKI, VIP and the Cochrane Library. Randomized controlled trials of XLGB for the treatment of related dis-eases were collected and evaluated, and the inclusion and exclusion criteria of documents were formulated. According to the Cochrane reviewer′s Handbook, the literature quality assessment and bias risk assessment were carried out on the literatures those met the inclu-sion criteria. RevMan 5. 1 statistical software was used for Meta analysis. Results A total of 40 literatures were included, including 3824 patients. The results of Meta-analysis showed, compared with conventional drug regimens, the incidence rate of xerostomia, consti-pation, liver dysfunction, and total ADR in the XLGB treatment group was lower, but the risk of diarrhea were increased [ RR=1. 441 ( 0. 611, 3. 399 ) , I2=0%, P=0. 940 ] . Subgroup analysis showed, compared with XLGB+conventional drug treatment group, the incidence rate of xerostomia, constipation and total ADR in the XLGB treatment group was lower, but the risk of diarrhea were increased [ RR=2. 000 ( 0. 506, 7. 905 ) , I2=0%, P=0. 323 ] . Conclusion Existing clinical studies show that XLGB is relatively safety and reliable, but has increased risk of diarrhea compared with conventional drug regimens.关键词
仙灵骨葆胶囊/药品不良反应/安全性/系统评价Key words
Xianling Gubao Capsules/adverse drug reaction/safety/system evaluation分类
医药卫生
